Skip to content

Raw materials at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$83.33M+37.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$89K0.0%
Precigen logo
PrecigenPGEN
$333K
HRO
HarrowHROW
$7.48M+46.3%
ALN
Alnylam PharmaceuticalsALNY
$11.69M-50.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryRawMaterials.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's raw materials.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's raw materials?
BioCryst Pharmaceuticals (BCRX) reported raw materials of $8.33M in Q1 2026.
How has BioCryst Pharmaceuticals's raw materials changed year-over-year?
BioCryst Pharmaceuticals's raw materials decreased by 4.7% year-over-year, from $8.74M to $8.33M.
What is the long-term trend for BioCryst Pharmaceuticals's raw materials?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's raw materials has grown at a 3.9% compound annual growth rate (CAGR), from $8.91M to $10M.
What does raw materials mean?
Unprocessed materials and components purchased for use in manufacturing, valued at cost.